VTP-200 was generally well-tolerated with no product-related serious adverse events (SAEs) Interim data showed encouraging initial immunogenicity results, particularly in relation to the E1, E2 and E6 ...
Interim data from two studies, HBV001 and HBV002, showed that in chronic Hepatitis B (CHB) patients the heterologous prime-boost vector combination, ChAdOx1-HBV + MVA-HBV (VTP-300), induced robust T ...
Preliminary phase 3 trial data indicate padeliporfin vascular targeted photodynamic therapy has favorable efficacy and acceptable safety for low-grade UTUC. The use of padeliporfin vascular targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results